Cargando…

Patient, Caregiver, and Nurse Preferences for Treatments for Bone Metastases from Solid Tumors

BACKGROUND: Bone-targeted agents (BTAs) used for the prevention of skeletal-related events (SREs) associated with metastatic bone disease possess different attributes that factor into treatment decisions. OBJECTIVE: The aim of this study was to evaluate preferences of patients, caregivers, and nurse...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Yi, Arellano, Jorge, Hauber, A. Brett, Mohamed, Ateesha F., Gonzalez, Juan Marcos, Hechmati, Guy, Gatta, Francesca, Harrelson, Stacey, Campbell-Baird, Cynthia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925690/
https://www.ncbi.nlm.nih.gov/pubmed/26821359
http://dx.doi.org/10.1007/s40271-015-0158-4
_version_ 1782439981190479872
author Qian, Yi
Arellano, Jorge
Hauber, A. Brett
Mohamed, Ateesha F.
Gonzalez, Juan Marcos
Hechmati, Guy
Gatta, Francesca
Harrelson, Stacey
Campbell-Baird, Cynthia
author_facet Qian, Yi
Arellano, Jorge
Hauber, A. Brett
Mohamed, Ateesha F.
Gonzalez, Juan Marcos
Hechmati, Guy
Gatta, Francesca
Harrelson, Stacey
Campbell-Baird, Cynthia
author_sort Qian, Yi
collection PubMed
description BACKGROUND: Bone-targeted agents (BTAs) used for the prevention of skeletal-related events (SREs) associated with metastatic bone disease possess different attributes that factor into treatment decisions. OBJECTIVE: The aim of this study was to evaluate preferences of patients, caregivers, and nurses for features of BTAs used to prevent SREs in patients with a self-reported physician diagnosis of bone metastasis from solid tumors. METHODS: Patients (n = 187), primary caregivers (n = 197), or nurses (n = 196) completed a web-enabled discrete-choice experiment (10-question survey) in which they chose between pairs of hypothetical profiles of BTAs. Each profile was defined by six key treatment attributes, including efficacy and safety (two each) and route/frequency of administration and cost (one each). The relative importance of treatment attributes and levels was estimated. RESULTS: The most important treatment attribute for patients and nurses was out-of-pocket cost, and for caregivers, treatment-related risk of renal impairment. Risk of renal impairment was the second most important attribute for patients and nurses, while time until first SRE was the third most important attribute for all respondents. For nurses, risk of osteonecrosis of the jaw was least important, and for patients and caregivers, mode of administration was least important. LIMITATIONS: Respondents considered hypothetical medications; therefore, their decisions may not have the same consequences as actual decisions. CONCLUSIONS: The perspectives of patients, caregivers, and nurses are integral when making treatment decisions about BTAs to prevent SREs associated with solid tumors. Identifying the relative importance of attributes of BTAs will aid in the proper selection of therapy in this setting, which may improve patient outcomes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40271-015-0158-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4925690
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-49256902016-07-12 Patient, Caregiver, and Nurse Preferences for Treatments for Bone Metastases from Solid Tumors Qian, Yi Arellano, Jorge Hauber, A. Brett Mohamed, Ateesha F. Gonzalez, Juan Marcos Hechmati, Guy Gatta, Francesca Harrelson, Stacey Campbell-Baird, Cynthia Patient Original Research Article BACKGROUND: Bone-targeted agents (BTAs) used for the prevention of skeletal-related events (SREs) associated with metastatic bone disease possess different attributes that factor into treatment decisions. OBJECTIVE: The aim of this study was to evaluate preferences of patients, caregivers, and nurses for features of BTAs used to prevent SREs in patients with a self-reported physician diagnosis of bone metastasis from solid tumors. METHODS: Patients (n = 187), primary caregivers (n = 197), or nurses (n = 196) completed a web-enabled discrete-choice experiment (10-question survey) in which they chose between pairs of hypothetical profiles of BTAs. Each profile was defined by six key treatment attributes, including efficacy and safety (two each) and route/frequency of administration and cost (one each). The relative importance of treatment attributes and levels was estimated. RESULTS: The most important treatment attribute for patients and nurses was out-of-pocket cost, and for caregivers, treatment-related risk of renal impairment. Risk of renal impairment was the second most important attribute for patients and nurses, while time until first SRE was the third most important attribute for all respondents. For nurses, risk of osteonecrosis of the jaw was least important, and for patients and caregivers, mode of administration was least important. LIMITATIONS: Respondents considered hypothetical medications; therefore, their decisions may not have the same consequences as actual decisions. CONCLUSIONS: The perspectives of patients, caregivers, and nurses are integral when making treatment decisions about BTAs to prevent SREs associated with solid tumors. Identifying the relative importance of attributes of BTAs will aid in the proper selection of therapy in this setting, which may improve patient outcomes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40271-015-0158-4) contains supplementary material, which is available to authorized users. Springer International Publishing 2016-01-28 2016 /pmc/articles/PMC4925690/ /pubmed/26821359 http://dx.doi.org/10.1007/s40271-015-0158-4 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research Article
Qian, Yi
Arellano, Jorge
Hauber, A. Brett
Mohamed, Ateesha F.
Gonzalez, Juan Marcos
Hechmati, Guy
Gatta, Francesca
Harrelson, Stacey
Campbell-Baird, Cynthia
Patient, Caregiver, and Nurse Preferences for Treatments for Bone Metastases from Solid Tumors
title Patient, Caregiver, and Nurse Preferences for Treatments for Bone Metastases from Solid Tumors
title_full Patient, Caregiver, and Nurse Preferences for Treatments for Bone Metastases from Solid Tumors
title_fullStr Patient, Caregiver, and Nurse Preferences for Treatments for Bone Metastases from Solid Tumors
title_full_unstemmed Patient, Caregiver, and Nurse Preferences for Treatments for Bone Metastases from Solid Tumors
title_short Patient, Caregiver, and Nurse Preferences for Treatments for Bone Metastases from Solid Tumors
title_sort patient, caregiver, and nurse preferences for treatments for bone metastases from solid tumors
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925690/
https://www.ncbi.nlm.nih.gov/pubmed/26821359
http://dx.doi.org/10.1007/s40271-015-0158-4
work_keys_str_mv AT qianyi patientcaregiverandnursepreferencesfortreatmentsforbonemetastasesfromsolidtumors
AT arellanojorge patientcaregiverandnursepreferencesfortreatmentsforbonemetastasesfromsolidtumors
AT hauberabrett patientcaregiverandnursepreferencesfortreatmentsforbonemetastasesfromsolidtumors
AT mohamedateeshaf patientcaregiverandnursepreferencesfortreatmentsforbonemetastasesfromsolidtumors
AT gonzalezjuanmarcos patientcaregiverandnursepreferencesfortreatmentsforbonemetastasesfromsolidtumors
AT hechmatiguy patientcaregiverandnursepreferencesfortreatmentsforbonemetastasesfromsolidtumors
AT gattafrancesca patientcaregiverandnursepreferencesfortreatmentsforbonemetastasesfromsolidtumors
AT harrelsonstacey patientcaregiverandnursepreferencesfortreatmentsforbonemetastasesfromsolidtumors
AT campbellbairdcynthia patientcaregiverandnursepreferencesfortreatmentsforbonemetastasesfromsolidtumors